Biora licenses wound healing project to Molnlycke
This article was originally published in Clinica
Executive Summary
Swedish company Biora has formed a licensing agreement with Molnlycke Health Care for a wound healing product, intended for use in the treatment of chronic skin ulcers. Molnlycke gets exclusive rights to develop and market the product worldwide, excluding Japan. Biora will get up to SKr45 million ($4.3 million), including SKr10 million upfront, from the arrangement.
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.